Liporaxel (Paclitaxel Oral Solution) – Breast Cancer | HongKong DengYue Medicine
- Generic Name/Brand Name: Paclitaxel / Liporaxel®
- Indications: Breast cancer
- Dosage Form: Oral solution
- Specification: 300 mg × 1 vial/box
Paclitaxel Oral Solution Application Scope
Paclitaxel Oral Solution is an oral formulation of paclitaxel developed to improve patient convenience and compliance. It is mainly indicated for the treatment of breast cancer, gastric cancer, non-small cell lung cancer, and ovarian cancer, offering a non-intravenous alternative for patients requiring long-term therapy.

Paclitaxel Oral Solution Characteristics
Ingredients: Paclitaxel Oral Solution
Properties: Clear to slightly opalescent solution
Packaging Specification: 300 mg × 1 vial/box
Storage: Store at 15–25°C, protect from light
Expiry Date: 24 months
Executive Standard: In-house standard
Approval Number: Imported Drug Registration No. H20190023
Date of Revision: November 2022
Manufacturer: Daehwa Pharmaceutical Co., Ltd. (South Korea)
Guidelines for the Use of Liporaxel
Dosage and Administration:
Recommended Dose: 200 mg/m² once daily (or per regimen)
Administration: Oral, taken on an empty stomach with water
Missed Dose: Take as soon as remembered unless close to next dose; do not double dose
Adverse Reactions:
Common Adverse Reactions: Nausea, vomiting, diarrhea, alopecia, fatigue, peripheral neuropathy
Serious Adverse Reactions: Myelosuppression, severe hypersensitivity reactions, hepatotoxicity, severe infections
Contraindications:
Hypersensitivity to paclitaxel or excipients
Severe baseline neutropenia or thrombocytopenia
Pregnancy and breastfeeding
Precautions:
Regular blood counts and liver function monitoring are required
Use with caution in patients with impaired hepatic function.
Risk of severe allergic reactions—premedication may be required.
Paclitaxel Oral Solution Interactions
Concomitant use with CYP3A4 inhibitors (e.g., ketoconazole, erythromycin) may increase paclitaxel exposure.
Concomitant use with CYP3A4 inducers (e.g., rifampin, phenytoin) may reduce efficacy.
Concomitant use with cisplatin or doxorubicin may increase the risk of toxicity.
Monitor closely when used with immunosuppressants or anticoagulants.
Note:
- If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
- This content is for reference only. Prescription drugs must be used under a doctor’s guidance and purchased from authorized sources.










Reviews
There are no reviews yet.